TrialLancet (London, England)2011

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.

Nicole Sherry et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.